Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $721.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Liabilities and Shareholders Equity fell 15.54% year-over-year to $721.0 million, compared with a TTM value of $1.5 billion through Sep 2025, down 26.88%, and an annual FY2024 reading of $782.7 million, up 108.51% over the prior year.
  • Liabilities and Shareholders Equity was $721.0 million for Q2 2025 at Autolus Therapeutics, down from $782.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $853.6 million in Q2 2024 and bottomed at $263.8 million in Q3 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $533.4 million, with a median of $455.5 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 23.43% in 2023, then soared 108.51% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $405.6 million in 2021, then rose by 20.89% to $490.3 million in 2022, then decreased by 23.43% to $375.4 million in 2023, then surged by 108.51% to $782.7 million in 2024, then decreased by 7.89% to $721.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AUTL at $721.0 million in Q2 2025, $782.7 million in Q4 2024, and $827.5 million in Q3 2024.